Peer-reviewedCC BY-NC-ND 4.0Translational Breast Cancer Research
Precision de-escalation in HER2-enriched breast cancer: promise and pitfalls of multiomic response predictors
- 1Division of Clinical Research and Technological Development, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
Related
- A comparative multiomic atlas of human immunity to multiple COVID-19 vaccines
- Multiomic analysis of human diabetic retinal disease reveals severity and region-specific impairment of the retinal neurovascular unit
- Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction
- ICONIC: An R Package for Integrating Instrumental Variable- and Negative-Control-Informed Causal Discovery and Diagnostics in Multiomic Studies
- Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib
BibTeX
@article{silva2026precision,
title = {{Precision de-escalation in HER2-enriched breast cancer: promise and pitfalls of multiomic response predictors}},
author = {Jessé Lopes da Silva and Andréia Cristina de Melo},
journal = {Translational Breast Cancer Research},
year = {2026},
month = sep,
doi = {10.21037/tbcr-2026-0032},
url = {https://doi.org/10.21037/tbcr-2026-0032},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Precision de-escalation in HER2-enriched breast cancer: promise and pitfalls of multiomic response predictors
AU - Jessé Lopes da Silva
AU - Andréia Cristina de Melo
PY - 2026
DA - 2026/09/21
JO - Translational Breast Cancer Research
DO - 10.21037/tbcr-2026-0032
UR - https://doi.org/10.21037/tbcr-2026-0032
SN - 2218-6778
ER -